Utah Becomes First State to Implement Permanent Screening for SMA

Leave a Comment / Advocacy, Front Page News, Our Impact /

The Utah Department of Public Health has announced that, effective immediately, all newborns born in the state will be screened for spinal muscular atrophy. This announcement makes Utah the first state to implement permanent SMA screening. Late last year, the Utah Newborn Screening Advisory Committee recommended that SMA be added to the state screening panel. […]

Utah Becomes First State to Implement Permanent Screening for SMA Read More »

Federal Committee to Vote on Spinal Muscular Atrophy Newborn Screening on Thursday

Leave a Comment / Advocacy, Front Page News, Our Impact /

On Thursday, February 8, the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), a federal committee that oversees newborn screening, will vote on whether to recommend newborn screening for spinal muscular atrophy. This decision is an important step toward our goal of having every baby born in the United States screened for SMA.

Federal Committee to Vote on Spinal Muscular Atrophy Newborn Screening on Thursday Read More »

Preliminary Data from FIREFISH Trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy

Leave a Comment / Clinical Trials, Front Page News, Research /

PTC Therapeutics, Inc. recently announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH study. FIREFISH is a two-part seamless, open-label, multi-center study to investigate the safety and efficacy of RG7916 in infants and babies with Type 1 SMA. RG7916 has been safe and well tolerated at all doses

Preliminary Data from FIREFISH Trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy Read More »

AveXis Releases Community Statement on Expanded Clinical Trials

Leave a Comment / Clinical Trials, Front Page News, Research /

AveXis has provided the following community statement on AVXS-101. Dear SMA Community, At AveXis, the gene replacement therapy company developing a new approach to treat SMA known as AVXS-101, we recently announced our plans to start three new clinical trials (STR1VE EU, SPRINT, REACH) in addition to our ongoing clinical trials (STR1VE, STRONG). The goal

AveXis Releases Community Statement on Expanded Clinical Trials Read More »

Cure SMA to Host Webinar on Treatment Access and Clinical Trials on February 15

Leave a Comment / Clinical Trials, Community Awareness, Front Page News /

On Thursday, February 15, at 12:00pm CST (10:00am PST/11:00am MST/1:00pm EST), Cure SMA will hold a webinar updating the community on treatment access and clinical trials. Among the topics covered will be:  The current status of Spinraza access, including dosing, sites, and insurance Updates on ongoing clinical trials Updates on upcoming clinical trials News from

Cure SMA to Host Webinar on Treatment Access and Clinical Trials on February 15 Read More »

SMA Industry Collaboration Releases Spinal Muscular Atrophy Voice of the Patient (VoP) Report

Leave a Comment / Advocacy, Front Page News, Our Impact, Research /

Cure SMA and our partners in the SMA Industry Collaboration are pleased to announce the release of the Spinal Muscular Atrophy Voice of the Patient (VoP) Report. This report is a thorough written account of the Patient-Focused Drug Development (PFDD) Meeting with the FDA, in the spring of 2017. Patient Focused Drug Development Meeting with

SMA Industry Collaboration Releases Spinal Muscular Atrophy Voice of the Patient (VoP) Report Read More »

2018 Updated SMA Drug Pipeline Released

Leave a Comment / Clinical Trials, Front Page News, Research /

We’ve recently released an update to the SMA drug pipeline. This latest version includes: 16 active programs, including one approved therapy.  14 pharmaceutical partners. 6 programs in clinical trials. An ever-increasing breadth of potential treatment approaches to SMA. Effective Treatments for All Ages, Stages and Types of SMA In December 2016, our community celebrated the approval

2018 Updated SMA Drug Pipeline Released Read More »

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

Leave a Comment / Clinical Trials, Research /

AveXis, a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today provided an overview of the expanded clinical development program for the company’s initial gene therapy candidate, AVXS-101, for the treatment of spinal muscular atrophy (SMA). In addition to the ongoing pivotal trial in SMA Type 1

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy Read More »

Scholar Rock Announces Plan to Bring Possible SMA Treatment into Clinical Trials

Leave a Comment / Clinical Trials, Front Page News, Research /

Scholar Rock, a biotechnology company based in Boston, has announced that they will be investing nearly $50 million to bring SRK-015, a muscle drug for possible treatment of SMA, into human clinical trials. SRK-015 is Scholar Rock’s lead clinical candidate. They expect to start clinical development in the first half of 2018, although timelines for

Scholar Rock Announces Plan to Bring Possible SMA Treatment into Clinical Trials Read More »

Cure SMA Launches Advocacy Action Network

Leave a Comment / Advocacy, Front Page News, Our Impact /

Working together, we’ve achieved tremendous success in advocating for ourselves, our families, and our whole community, particularly in the past few years. Today, we’re building on this momentum with the launch of our Advocacy Action Network. The Advocacy Action Network will allow our advocates to share their voices on issues that impact our community, including research

Cure SMA Launches Advocacy Action Network Read More »

Scroll to Top